India is entering a new phase in its battle against tuberculosis (TB) with the potential introduction of two novel vaccines developed by Cadila Pharmaceuticals Ltd and the Serum Institute of India. These vaccines, pending approval from the drugs regulator, were evaluated in a large Phase III clinical trial led by the Indian Council of Medical Research (ICMR) and published in The British Medical Journal. The trial involved over 12,700 participants, primarily household contacts of TB patients, and highlighted the vaccines' efficacy in preventing extra-pulmonary TB, with VPM1002 showing 50.4% efficacy after three years. Despite the ongoing TB burden, which accounts for about 27 lakh new cases in India annually, the country has set an ambitious target to eliminate TB by 2025. The new vaccines could be produced at a cost of less than ₹100 (roughly $1.20 USD) per dose, potentially enabling large-scale vaccination in high-risk groups. While these vaccines are not a 'magic bullet,' they represent significant progress in India's public health strategy against TB, particularly in preventing severe forms of the disease that lead to high morbidity and mortality.